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ABSTRACT
Phosphatases have long been regarded as tumor suppressors, however there 
is emerging evidence for a tumor initiating role for some phosphatases in several 
forms of cancer. Low Molecular Weight Protein Tyrosine Phosphatase (LMWPTP; acid 
phosphatase 1 [ACP1]) is an 18 kDa enzyme that influences the phosphorylation 
of signaling pathway mediators involved in cancer and is thus postulated to be a 
tumor-promoting enzyme, but neither unequivocal clinical evidence nor convincing 
mechanistic actions for a role of LMWPTP have been identified. In the present study, 
we show that LMWPTP expression is not only significantly increased in colorectal 
cancer (CRC), but also follows a step-wise increase in different levels of dysplasia. 
Chemical inhibition of LMWPTP significantly reduces CRC growth. Furthermore, 
downregulation of LMWPTP in CRC leads to a reduced migration ability in both 2D- and 
3D-migration assays, and sensitizes tumor cells to the chemotherapeutic agent 5-FU. 
In conclusion, this study shows that LMWPTP is not only overexpressed in colorectal 
cancer, but it is correlated with the malignant potential of this cancer, suggesting 
that this phosphatase may act as a predictive biomaker of CRC stage and represents 
a rational novel target in the treatment of this disease.
INTRODUCTION
Colorectal cancer (CRC) is one of the most common 
forms of cancer in the Western world. Although CRC 
mortality has been progressively declining since 1990, 
it still remains the second most common cause of cancer 
death in the US and Europe [1]. When in a non-metastatic 
state, surgery of the primary tumor is considered a curative 
treatment. Unfortunately, around 20% of the CRC patients 
already present with metastatic disease, dropping the 
5-year survival rate from 90% to a dramatic 12% [2]. For 
this reason, treatments focusing on the prevention of this 
progression into the metastatic state are urgently called for. 
All cellular functions are under tight control of the 
balance between phosphorylation and dephosphorylation 
of proteins. Like many neoplasms, disturbed protein 
phosphorylation patterns, indicating imbalanced kinase 
and/or phosphatase activities, are often observed in 
colorectal cancer [3]. So far, kinases have received most 
of the attention in cancer studies, as it is well established 
that deregulation of these enzymes can contribute to the 
development of multiple neoplasms [4]. Inhibitors of 
kinase activities, such as EGFR- and BRAF-inhibitors, are 
amongst the novel potential treatments currently explored 
for CRC. Despite the fact that these drugs have shown 
some promising results [5, 6], there is still a need for 
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new, additional, classes of molecules as potential targets. 
Phosphatases could present such a class.
Generally assumed to be tumor suppressive by 
counteracting kinase activities, phosphatases have largely 
been ignored as viable targets for treatment. However, 
a tumor promoting role has also been suggested for 
certain phosphatases [7]. One of these is the ubiquitously 
expressed Low Molecular Weight Protein Tyrosine 
Phosphatase (LMWPTP), encoded by the gene ACP1. 
Enhanced mRNA expression of this phosphatase has 
been reported for some human tumors [8, 9]. This 18kDa 
protein tyrosine phosphatase can have a positive effect on 
cell growth and proliferation signaling by interacting with 
several molecules involved in these processes, such as 
Ephrin A2 receptor (EphA2) [10], β-catenin [11], platelet-
derived growth factor receptor (PDGFR) [12], Janus 
kinase (JAK)-2 [13], and signal transducer and activator 
of transcription (STAT)-5 [14].
The aim of this study was to examine the expression 
levels and potential role of LMWPTP in colorectal 
cancer. Our study reveals a novel unexpected action of 
hypomethylation-mediated upregulation of LMWPTP 
mRNA and protein levels in primary colorectal cancer and 
shows that this upregulation mediates chemoresistance and 
increased migration that characterizes this infaust disease.
RESULTS
ACP1 mRNA expression is increased in 
colorectal adenomas and carcinomas
To understand the role of LMWPTP in colorectal 
cancer, we first investigated the gene expression levels of 
ACP1 using publicly available microarray datasets from 
Affymetrix Platforms. Expression of the LMWPTP encoding 
gene ACP1 (transcript 215227) was compared between CRC 
and normal adjacent colonic tissue (n = 17), and found to be 
significantly increased in the carcinoma group (P = 0.0005, 
Figure 1A). Colon cancer follows the adenoma to carcinoma 
sequence, and most cancers arise from dysplastic adenomas. 
Therefore, we also examined ACP1 expression levels in 
adenoma samples and again observed an increased mRNA 
expression in these samples (n = 32) compared to their 
normal adjacent colon tissue (P < 0.0001, Figure 1B).
LMWPTP protein is overexpressed in primary 
colorectal cancer samples
Next, we examined whether the increased ACP1 
expression corresponds to increased protein levels of 
LMWPTP in CRC samples. Immunohistochemistry was 
performed on tissue sections of biopsies of low grade 
dysplasia (LGD; n = 9), high grade dysplasia (HGD; n = 7) 
adenocarcinoma (n = 12) and controls (n = 8) (Figure 1C). 
LMWPTP expression in intestinal epithelial cells (IEC) 
was limited to 9 ± 9% of cells in non-cancerous tissues. 
In contrast, expression of LMWPTP was significantly 
increased with subsequent levels of dysplasia (41 ± 
33% and 80 ± 29% positive IEC in LGD and HGD, 
respectively), with up to 100% of LMWPTP-positive IECs 
in adenocarcinoma (Figure 1D). In addition to increasing 
numbers of positive cells, the intensity of the staining 
also increased in the untransformed-to-colorectal cancer 
sequence (0.44 ± 0.18, 0,72 ± 0.36, 1.50 ± 0.79 and 3.14 
± 0.90 in control, LGD, HGD, and CRC respectively, 
Figure 1E). Furthermore, LMWPTP overexpression is 
preserved in liver-metastasized CRC tumor cells, with 100% 
of IECs highly positive for this phosphatase (note that the 
normal liver tissue stains negative for LMWPTP) (n = 5).
To validate these results using a different 
technique, we examined LMWPTP expression in 6 
paired freshly frozen tumor and normal adjacent tissues 
by Western blotting, again demonstrating a significant 
increase in the total levels of this phosphatase in the 
tumor tissue (Figure 2A, 2B).
To confirm the increased LMWPTP protein 
expression in a larger sample group, the staining was 
subsequently performed on a tissue micro array (TMA) 
containing samples of 72 colorectal adenoma and/or 
carcinoma patients (Table 1; representative samples shown 
in Figure 2C). After excluding poor quality cores, 62 cores 
of CRC tissue, 25 cores of adenoma tissue and 65 cores of 
healthy adjacent tissue were available for analysis. Again, 
the cores were scored for percentage positive IECs and 
intensity of the staining. The mean percentage positive 
IEC was 27 ± 3% in normal adjacent tissues compared 
to 64 ± 4% in adenoma and 90 ± 3% in carcinoma 
(P < 0.001, Figure 2D). In addition, the intensity of 
the staining similarly increased from healthy tissue to 
adenoma and CRC (0.63 ± 0.05, 1.22 ± 0.10 and 1.90 ± 
0.09, respectively, P < 0.001, Figure 2E). For 15 patients 
there was material available for all three stages. In these 
patients, a significant increase in LMWPTP expression 
from normal to adenoma, and adenoma to carcinoma 
tissue was observed (37 ± 6%, 67 ± 7% and 97 ± 1%, 
respectively, P < 0.001, Figure 2F), suggesting a role for 
LMWPTP in the oncogenic transformation of colonic 
epithelial cells. Due to the high expression of LMWPTP 
in all our carcinoma samples, we were unable to correlate 
clinical parameters such as Dukes’ stage or patient survival 
to LMWPTP expression in cancer. However, when 
correlating patient survival to LMWPTP expression in their 
normal tissue, a higher LMWPTP expression in healthy 
tissue was significantly correlated to increased disease 
related mortality (Spearmans rho correlation P = 0.026, 
Supplementary Figure S1A). These data suggest either 
that there are infiltrating tumor cells present in what we 
denominate as normal adjacent tissue, or that an increased 
LMWPTP expression in normal cells is predictive or 
conductive to cellular transformation. Together, these 
results show that LMWPTP is overexpressed in a stepwise 
manner from normal tissue to carcinoma.
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One of the mechanisms which may contribute to 
upregulation of LMWPTP expression levels, could be 
based on an altered methylation pattern of ACP1. Using an 
in silico analysis with the online database MENT (http://
mgrc.kribb.re.kr:8080/MENT/) [15], we observed that 
ACP1 is hypomethylated in colon cancer as compared to 
normal colonic tissue (n = 680; P < 0.0001), providing a 
possible explanation for the observed upregulation of gene 
expression (Supplementary Figure S1B).
Effect of inhibition of LMWPTP on cell survival
As our data in primary CRC indicates that an 
increased LMWPTP expression may contribute to tumor 
progression, we wondered whether inhibition of LMWPTP 
might reverse any of the oncogenic processes involved. The 
only LMWPTP inhibitor available to date is PLP, an active 
derivative of Vitamin B6, which has been shown to inhibit 
LMWPTP activity by interacting with the Asp129 site [16]. 
To confirm the effectiveness and selectivity of this compound, 
we precipitated LMWPTP and two other phosphatases with 
activity towards the substrate PNPP (SHP-1 and PTP1B) from 
CRC cells and demonstrated that the phosphatase activity of 
LMWPTP was indeed decreased in the presence of PLP, while 
the activity of SHP-1 and PTP1B were unaffected (Figure 
3A and Supplementary Figure S2A). Next, we treated CRC 
cells (CACO-2 and HCT116), as well as the non-transformed 
human gastrointestinal epithelial cell line EPC2-hTERT and 
freshly isolated PBMCs, with this compound and assessed 
cell viability. As shown in Figure 3B, PLP dose-dependently 
reduced viable cell numbers of the CRC lines, while 
non-transformed cells are hardly affected by this treatment. 
Figure 1: ACP1 mRNA and LMWPTP protein expression are increased in colorectal dysplasia and carcinoma as 
compared to non-dysplastic tissue. (A, B) Using publicly available gene expression data from Affymetrix platforms, ACP1 expression 
(transcript 215227) was analyzed in carcinoma tissue (CRC) and adjacent normal colon tissue. Significantly higher expression of ACP1 
mRNA expression was observed in carcinoma tissues (n = 17, P = 0.0005 by student’s T-test). Gene expression array comparing ACP1 
expression in colorectal adenoma to normal adjacent tissue shows increased ACP1 mRNA expression in cancer tissues (n = 32, P < 0.0001) 
(C). Tissues of patients with inactive ulcerative colitis (UC, n = 8), low grade dysplasia (n = 8), high grade dysplasia (HGD, n = 6), 
colorectal cancer (CRC, n = 12) and CRC liver metastasis (n = 5) were stained for LMWPTP by immunohistochemistry. Representative 
examples (10x and 40x magnifications) of UC, LGD, HGD, CRC and liver metastasis are shown. (D, E) LMWPTP staining was scored for 
percentage of positive intestinal epithelial cells as well as intensity of staining and statistical analysis was performed using Mann-Whitney 
t-test. (*P > 0.05; ** P > 0.01, *** P > 0.001).
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PLP induced a G0/G1 cell cycle arrest in the cancer cells 
(Figure 3C and Supplementary Figure S2C). Furthermore, 
PLP treatment concomitantly caused apoptosis in CRC cells, 
as shown by an increased Annexin V staining (Figure 3D and 
Supplementary Figure S2B). Thus, these data suggest that 
chemical inhibition of LMWPTP may reduce CRC growth.
As PLP may have some off-target effects (LMWPTP 
is not the only molecular target to be inhibited by this 
compound), we decided to further investigate the effect 
of inhibition of LMWPTP by specifically reducing its 
expression. We employed shRNA against ACP1 to stably 
knock down LMWPTP in HCT116 and CACO-2 cells, 
which reduced the expression of this phosphatase by 
50% (Figure 3E). However, while chemical inhibition of 
LMWPTP affected cell viability and cell cycling, knockdown 
of LMWPTP did not (Figure 3F and Supplementary Figure 
S2D–S2F). This is perhaps not surprising, as knock down of 
LMWPTP was not complete, and the creation of stable cell 
lines would necessarily select for cells escaping cell death.
LMWPTP induces drug resistance
Whilst not inducing cell death, knock down of 
LMWPTP in CRC lines allowed us to further investigate 
Figure 2: LMWPTP protein expression is increased in CRC as compared to paired normal adjacent tissue, and 
expression increases during the canonical progression sequence from normal tissue via adenoma to carcinoma.  
(A) Freshly frozen paired tumor (T) and normal adjacent (N) colonic tissue samples of 6 patients were lysed in Laemmli buffer, and 
LMWPTP expression was determined using western blot analysis. β-Actin served as loading control. (B) Quantification of western blot 
results using Li-Cor Odyssey software presented as boxplot of mean, as well as comparisons of individual patient’s samples (*P < 0.05; **P 
< 0.01). (C) IHC analysis of LMWPTP on a tissue micro array (TMA) of patients with colorectal cancer (n = 65), colorectal adenoma (n = 
25), and healthy adjacent tissue (n = 62). Representative stainings (20x and 40X inset) of tissue cores from carcinoma, adenoma and healthy 
tissue are shown. (D–E) Staining was scored for percentage of LMWPTP positive intestinal epithelial cells as well as intensity of staining. 
Statistical analysis was performed using Mann-Whitney t-test. (F) Percentage of LMWPTP positive IEC were compared in patients from 
whom normal, adenoma and CRC tissue were all available (n = 15, Wilkinson paired t-test) (*P< 0.05; **P < 0.01; ***P < 0.001).
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Table 1: Patients characteristics of tissue micro array
Parameter Mean (SD) or N (%)
Number of Patients 72 (100%)
Healthy cores available 65 (90%)
Adenoma cores available 25 (35%)
Carcinoma available 62 (86%)
Age at presentation
Mean 69.85 (11.8)
Median 70
Range 30–92
Sex, N (%)
Male 37 (51.4%)
Female 35 (48.6%)
Dukes’ stage
A 1 (1%)
B 38 (47%)
C 23 (28%)
D 10 (12%)
Status
Living 44 (61%)
Non-CRC-related death 13 (18%)
CRC-related death 15 (21%)
Figure 3: Effects of chemical inhibition and knockdown of LMWPTP on the oncogenic potential of colorectal cancer 
cells. (A) Immunoprecipitated phosphatases (LMWPTP, PTP1B and SHP-1) from HCT116 lysates were incubated with the only known 
inhibitor of LMWPTP, PLP, resulting in reduction of LMWPTP phosphatase activity in LMWPTP precipitates, while enzymatic activity 
of the two other PNPP phosphatases remain unaffected upon PLP treatment. (B) Treatment of colorectal cancer cell lines (HCT116 and 
CACO-2) with PLP dose-dependently reduced viable cell numbers as determined by MTT assay, while non-transformed cell lines (EPC2-
hTERT and PBMCs) are hardly effected. (C) Propidium-iodine staining of CACO-2 cells followed by FACS analysis shows that PLP 
treatment induces a G0/G1 cell cycle arrest. (D) PLP treatment of CRC cells results in apoptosis, as shown by FACS analysis with 
Annexin V/PI staining on CACO-2 cells treated either with 500 uM PLP or vehicle. (E) Stably transfected cell lines were created, by 
lentiviral transfection of HCT116 and CACO-2 cells with shRNA against LMWPTP. This resulted in cell lines harboring a knockdown of 
approximately 50% as compared to non-target transfected control cells. (F) LMWPTP knockdown does not affect overall cell proliferation 
as shown by MTT assay.
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the role of LMWPTP in other oncogenic processes. We 
started by determining some of the molecular targets of 
LMWPTP. Figure 4A shows that knock down of LMWPTP 
resulted in the downregulation of several cancer-associated 
signaling pathways. Most noticeably, we observed a 
reduced phosphorylation of the epidermal growth factor 
receptor (EGFR) and diminished phosphorylation of 
protein kinase B (PKB) both on the threonine 308 and 
serine 473 sites in LMWPTP knockdown cells (Figure 4A). 
In addition to proliferation, these molecules are implicated 
in cell survival, and we therefor speculated that LMWPTP 
knockdown cells might be more susceptible to cytostatic 
agents. Indeed, treatment of CRC cells with 5-fluorouracil 
(5-FU), a commonly used chemotherapeutic, caused a dose 
dependent decrease in viable cell numbers, which was 
significantly more pronounced in LMWPTP knock down 
cells (Figure 4B and Supplementary Figure S3A). Thus, 
silencing of LMWPTP confers drug sensitivity of CRC 
cells, possibly through loss of EGFR and PKB activity. 
Other mechanisms used by tumor cells to escape drug 
effects include the expression and regulation of multidrug 
resistance efflux pumps. These include p-glycoprotein, 
also known as multidrug resistance protein 1 (MDR1), 
which transports several substrates across the extracellular 
membrane. Interestingly, P-gp was expressed on CACO-
2 cells, and its expression was reduced upon silencing of 
LMWPTP (Figure 4C). In contrast, HCT116 cells did not 
express this particular efflux pump (and hence no decrease 
was observed in LMWPTP knock down cells), suggesting 
that different mechanisms may contribute to drug sensitivity 
in different CRC lines (Supplementary Figures S3B).
LMWPTP targets migration signaling
Colorectal cancer is a frequently fatal disease 
because of its high propensity to migrate and invade other 
tissues, preventing curative surgical treatment. Cellular 
migration is dependent on the tight regulation of assembly 
and disassembly of focal adhesion sites. This process is 
mediated the by the formation of a FAK–Src complex, 
and phosphorylation of FAK-associated substrates such as 
paxillin and p130cas, all known to be required for cell motility 
[17]. Our biochemical analysis of LMWPTP deficient 
cells revealed reduced FAK Tyr-397 phosphorylation in 
these cells, suggesting that LMWPTP may function in this 
pathway to promote FAK Tyr-397 phosphorylation and 
the formation of membrane extensions characteristic of 
migrating cells (Figure 2A). We therefore investigated the 
effects of LMWPTP downregulation in colorectal cancer 
cell lines on their ability to migrate. Confluent plates of 
CACO-2 and HCT116 cells were scratched using a pipet 
tip, and cell migration into the wound was assessed after 
24 h and 48 h. LMWPTP knock down cells showed a 
significant delay in the ability to migrate into the empty 
space (Figure 5A–5B and Supplementary Figures S4A–
S4B, N.B. that HCT116 is a slower migrating cell line). 
To verify the positive role of LMWPTP in cell migration, 
we used a second, different approach to investigate cellular 
movement, which does not rely on wounding the CRC 
monolayer. Using time-lapse microscopy of cell migration 
we again observed that CACO-2 and HCT116 LMWPTP 
knockdown cells are significantly impaired in their total 
migration, and thereby also the cell velocity. Strikingly, 
the effective migration, which is defined as the directional 
movement of the cells to the cell-free center, was even more 
reduced (Figure 5C–5D and Supplementary Figures S4C–
S4D ), Supplementary Movies). We subsequently went on 
to assess the role of LMWPTP on migration in a 3D-setting, 
representing the invasive capacity of these cells. Beads were 
coated with CACO-2 and HCT116 knockdown or control 
cells, and were settled in a collagen matrix. Cell dispersion 
from the bead into the surrounding collagen matrix was 
measured. Although not reaching statistical significance, 
we observed a trend towards reduced invasive capacity 
upon LMWPTP knock down for both cell lines (Figure 
5E–5F and Supplementary Figure S4E–S4F). Together 
these data demonstrate that knocking down LMWPTP in 
colorectal cancer cells reduces their migratory capacity, and 
is especially important for directional cell migration.
Different mechanisms for reduced migratory 
responses in CRC cells
As both CACO-2 and HCT116 cell lines 
demonstrated reduced FAK activity and subsequent 
migration upon LMWPTP knock down, we next set out to 
further examine the underlying mechanism of this reduced 
migration. First we investigated the adhesive capacity of 
these cell lines, adhesion being indispensable for proper 
migration, and FAK being a major regulator of this process. 
As shown in Figure 6A, full adherence of CACO-2 non-
target cells to the glass surface was reached after 30 minutes 
and 1 h, while only 50% of the knockdown cells adhered to 
the bottom of the wells within these time points (P > 0.05). 
In contrast, HCT116 cells were much slower to adhere, and 
no differences could be observed between LMWPTP knock 
down and control cells (Figure S5A).
Next, we employed confocal microscopy to 
investigate the actin distribution as well as cellular 
morphology of the cells. We found alterations in the 
cytoskeletal F-actin composition in HCT116 cells 
downregulated for LMWPTP. Loss of LMWPTP resulted 
in a more stretched appearance of cells, suggestive of a less 
migratory phenotype (Figure 6B). This is also reflected 
by our morphometric analysis (Figure 6C), which reveals 
a significantly higher length/width ratio in the LMWPTP 
knockdown cells (1.1 ± 0.02 in control cells and 1.7 ± 
0.18 knockdown cells; P < 0.0001). In contrast, CACO-2 
cells, which have a cuboidal appearance, did not show the 
stretching in the knockdown cells observed in the HCT116 
cell line (Supplementary Figure S5B). These results indicate 
that while the net effect of LMWPTP on migration is 
similar in CACO-2 and HCT116 cell lines, the underlying 
mechanisms differ, emphasizing the heterogeneity of CRC.
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DISCUSSION
In this study we identify LMWPTP overexpression 
as a mediator for increased chemoresistance and migration 
in colorectal cancer. We show for the first time, that 
LMWPTP protein expression is drastically increased in 
primary colorectal cancer samples as compared to normal 
adjacent tissue. LMWPTP expression appears to follow 
a step-wise increase from healthy tissue, to dysplastic 
adenoma, and to carcinoma. Deregulated transcription 
and translation is a common phenomenon of cancer 
cells, and many signaling pathways can concomitantly 
be affected in malignant cells. However, analysis of other 
phosphatases in CRC sections does not indicate a general 
upregulation of PTPs in this tumor type (unpublished 
results), indicating a specific oncogenic role for LMWPTP 
in the transformation of colon epithelial cells. While the 
cause of the specific upregulation of ACP1 mRNA has yet 
to be identified, interestingly, an initial database analysis 
(MENT methylation and expression database) suggests 
that this gene is hypomethylated in adenoma and cancer 
samples.
Thus far, while several phosphatases have been 
shown to act as tumor suppressors, few phosphatases 
have been implicated as oncogenes in colorectal cancer. 
Phosphatase of regenerating liver-3 (PRL-3), also known 
as PTP4A3, was shown to be upregulated in up to 100% 
of CRC liver metastasis cases, and is overexpressed in 
primary tumors [18]. Furthermore, PRL-3 can promote 
migration and invasion by enhancing MMP2 activity 
[19]. Similarly, the phosphatase SAP-1 has been shown 
to be overexpressed in colorectal tumors, and especially 
promotes the tumorigenic potential of intestinal epithelial 
cells [20, 21]. Likewise, PTPα is capable of activating 
Src protein kinase activity in colorectal cancer, further 
supporting the idea that phosphatases not only act as 
inhibitors of oncogenic kinases, but can function as tumor 
promoters as well [22]. To this relatively short list, we may 
now add LMWPTP. Although these other phosphatases 
may also be implicated in the colorectal cancer process, 
convincing demonstration of their dysregulation in a large 
cohort of well-characterized colon cancer patients as well 
as detailed mechanistic insight into their exact role in the 
cancer process is largely lacking. In contrast, LMWPTP 
appears a bona-fide mediator of the CRC invasiveness and 
chemoresistance.
After our initial finding that LMWPTP is 
significantly overexpressed in colorectal cancer, we 
evaluated the effect of LMWPTP in vitro. Up to now, the 
most potent compound known to inhibit LMWPTP activity 
is the active form of vitamin B6, PLP. Interestingly, earlier 
reports have shown that both vitamin B6 and PLP serum 
levels are inversely correlated with colorectal cancer 
risk [23]. Our data suggest that inhibition of LMWPTP 
through Vitamin B6 may provide one possible explanation 
for these findings. Indeed, in pituitary cells PLP has been 
shown to induce cell cycle arrest [24], which corresponds 
well with the cell cycle block and apoptosis observed in 
our study, and suggests that LMWPTP inhibition may be a 
valuable avenue for treatment of CRC. Earlier reports have 
suggested that LMWPTP could modulate chemoresistance 
of cancer cells [25]. The current treatment protocol 
for advanced CRC contains chemotherapy, such as 
5-fluorouracil. Typically, the first course of chemotherapy 
is highly beneficial, but tumor cells tend to make use of 
several mechanisms to escape the therapy and become 
resistant. We now show that LMWPTP could be involved 
in these mechanisms in CRC. In addition to an increased 
sensitivity to chemotherapy, LMWPTP knock down cells 
showed a great reduction in phosphorylated EGFR and 
Figure 4: LMWPTP influences cell survival pathways and desensitizes colorectal cancer cells to chemotherapy. (A) Western 
blot analysis of LMWPTP knockdown and control cells reveals reduced phosphorylation of Epidermal Growth Factor Receptor (EGFR), 
Protein Kinase B (PKBt and PKBs) and FAK in the knockdown cells. (B) CACO-2 LMWPTP knockdown and control cells were treated 
with increasing concentrations of 5-fluorouracil and cell viability was assessed by MTT assay after 96 h. CACO-2 knockdown cells were 
more susceptible to 5-fluorouracil as compared to control (*P < 0.05). (C) P-glycoprotein expression on CACO-2 cells was determined by 
FACS analysis, using anti-P-gp and anti-mouse-FITC antibodies. P-gp expression is reduced upon LMWPTP knockdown in CACO-2 cells, 
as shown by FACS mean fluorescence intensity (MFI).
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Figure 5: Modulation of LMWPTP results in impaired migration and invasion in colorectal cancer cells. (A, B) HCT116 
cell migration was measured by scratch assays, where simple scratch wounds were made using a pipet tip, and pictures are taken at 0 h, 
24 h, and 48 h. Persistent area of clear plastic was measured and statistical analysis was performed using student’s T-test. (C, D) Two-
dimensional migration was analyzed using a ring-barrier system. HCT116 cell migration on gelatin was tracked during 24 h, with locations 
being captured using time-lapse microscopy every 12 min (x=start, line=cell track) (C). Quantification of migrated path indicates that the 
total migration and velocity were significantly reduced in LMWPTP knockdown cells. Effective migration and thereby efficiency are even 
further reduced. (D; *P < 0.05; **P < 0.01; ***P < 0.001). (E, F) Beads were coated with either CACO-2 LMWPTP knockdown or control 
cells for 24 hours, and embedded in a collagen gel matrix. Cells were allowed to invade the collagen matrix, and pictures were taking at 
0 h, 24 h, and 48 h (examples in E). The cell dispersion from the bead (arrow) into the collagen matrix was measured, and a trend towards 
reduced invasion was observed in LMWPTP knockdown cells. Data represents at least four beads (F).
Figure 6: LMWPTP influences cell adhesion and cell morphology. (A) CRC cell adhesion was determined by MTT assay of 
adherent cells after indicated time points, with fibronectin (FN) coating serving as control. CACO-2 LMWPTP knockdown cells adhere less 
than control cells (*P < 0.05; **P < 0.01). (B, C) Confocal microscopy of Phalloidin-rhodamine stained cells was employed to examine cell 
morphology. Immunofluorescence reveals a more elongated morphology in HCT116 LMWPTP knockdown cells as compared to control 
(B). To quantify the changes in morphology, the ratio between the length and width of the cells was calculated, with a higher ratio indicating 
a more elongated shape. Non-target control cells have a significantly lower ratio compared to LMWPTP knockdown cells. (1.1 ± 0.02 vs 
1.7 ± 0.18, n = 26; P < 0.0001) (C).
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PKB, making it tempting to speculate that decreased 
activity of these survival signals contributes to drug-
sensitivity of these cells. In addition, multidrug resistance 
pumps, such as P-gp are often upregulated on cancer cells 
and can contribute to decreased drug-sensitivity of tumors 
[26, 27]. Our study suggests that LMWPTP can act on 
these transporters as well, thereby contributing to the 
chemoresistance of CRC cells.
In this study, we observed clear differences between 
HCT116 and CACO-2 cells. While LMWPTP knock down 
conferred drug sensitivity in both cell lines, no modulation 
of P-gp was observed in HCT116 cells, suggesting 
different underlying mechanisms. In addition, while 
migratory and invasive behavior was impaired in both 
LMWPTP knock down cell lines, the molecular pathways 
contributing to migratory defects appeared to differ. 
Both cell lines demonstrated reduced phosphorylation 
of the focal adhesion kinase FAK. This kinase, by 
forming a complex with p120RasGAP and p190RhoGAP 
(p190A), leads to phosphorylation of p190A, resulting in 
polarity cues and increased directional movement [28]. 
Impaired formation of the Ras-Rho complex as a result 
of LMWPTP downmodulation may thus contribute to 
the inefficient cell movement and polarity observed in 
our migration assays. FAK is a major regulator in the 
adhesion to matrix, which is also essential for proper 
migration. However, while we observed adhesion defects 
in LMWPTP knock down CACO-2 cells, the same was 
not observed in HCT116 cells. This second LMWPTP 
knock down cell line selectively demonstrated a changed 
morphology and F-actin rearrangement, characteristic 
for sessile behavior of cells. These latter findings are 
reminiscent of (colorectal) cancer cells in which a more 
rounded morphology as a result of overexpression of 
RhoA correlated to increased ability to migrate in vitro 
and metastasize in vivo [29]. Thus, while inhibition of 
LMWPTP in both of these colorectal cancer lines appears 
beneficial in terms of reducing cell growth, drug resistance 
and metastatic potential, the mechanisms through which 
this is achieved may rely on genetic identity of the tumor 
cells. These data highlight the need for personalized 
medicine in cancer treatment, as different genetic 
backgrounds may affect the usefulness of treatment 
regimens as well as the molecular mechanisms behind 
them. This was recently very clearly demonstrated by the 
report of a selective benefit of mTOR inhibitors only in 
patients carrying PTEN-deficient tumors [30].
In summary, we show that low molecular weight 
protein tyrosine phosphatase is overexpressed in primary 
human colorectal cancers at both mRNA and protein level 
and that this phosphatase can function as an oncogene, by 
enhancing the migration, adhesion and chemoresistance in 
colorectal cancer cells. Together, this indicates that LMWPTP 
expression is a determining factor in the malignant potential 
of colorectal cancer, and suggests that this phosphatase 
provides a target in the fight against this devastating disease.
MATERIALS AND METHODS
Gene expression profiles
Expression profiles from publicly available NCBI 
GEO datasets were browsed to find comparisons of CRC 
or colorectal adenoma samples to their adjacent normal 
tissue. Information on ACP1 expression was available 
in 2 arrays. Dataset Record GDS4382 (transcript 
215227_x_at), based on the Affymetrix Human Genome 
U133 Plus 2.0 Array, was used to compare 17 paired 
CRC and adjacent normal tissue samples [31]. The same 
platform was used in dataset record GDS2947 (transcript 
215227_x_at), used to compare 32 paired colorectal 
adenoma and adjacent normal tissue samples [32]. P-
values were calculated per probe using Student’s t-tests.
Patient selection
At the Erasmus MC Formalin fixed paraffin 
embedded (FFPE) colorectal tissue specimens were 
collected from the department of pathology for 9 low 
grade dysplasia (LGD) patients, 5 high grade dysplasia 
(HGD) patients, 7 adenocarcinoma (CRC) patients and 
5 patients with CRC-related liver metastasis. Patients 
with active and inactive ulcerative colitis (n = 8) served 
as controls.
In addition, a tissue micro array was constructed 
at the Leiden University Medical Centre (LUMC), 
containing material from 72 patients with colorectal 
cancer. Representative cores of healthy adjacent tissue 
were available for 65 patients, 25 patients had available 
adenoma cores, and 62 patients had representative 
carcinoma cores.
Immunohistochemistry
The FFPE tissue sections and TMA were 
immunohistochemically stained for LMWPTP (Acp1 
antibody, sc-100343, Santa Cruz Biotechnologies, 
Dallas, Tx) as described [33]. Briefly, 5 μm sections were 
deparaffinized in xylene and rehydrated through graded 
alcohols. Antigen-retrieval was performed by boiling the 
slides in citrate buffer pH 6.0 for 15 minutes. Endogenous 
peroxidases were blocked by immersing the slides for 
10 minutes in 3% H2O2 in phosphate buffered saline 
(PBS). Next, slides were blocked by incubation in PBS 
containing 10% goat serum in for 1 h at RT. Primary 
antibody was added 1:100 in blocking buffer and 
incubated overnight at 4°C. Envision goat anti-mouse-
horseradish peroxidase (Dako, Heverlee, Belgium) was 
used as secondary antibody. The slides were scored for the 
percentage of positive epithelial cells as well as intensity 
of the staining on a 4 scale scoring system. P-values were 
calculated using Student’s t-tests and Wilcoxon signed-
rank test for the paired samples.
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Cell lines
HCT116 and CACO-2 colorectal cancer cells were 
purchased from ATCC (Manassas, USA) and cultured in 
Dulbecco’s Modified Eagles Medium (DMEM, Lonza, 
Basel, Switzerland), supplemented with 10% fetal 
bovine serum (Sigma-Aldrich, St. Louis, USA). EPC2-
hTERT cells are cultured in Keratinocyte-SFM medium 
(Life technologies, Bleiswijk, NL), supplemented with 
Epidermal Growth Factor (EGF) and Bovine Pituitary 
Extract (BPE). All cell cultures were supplemented 
with 100 U/ml penicillin, 100 mg/ml streptomycin (Life 
technologies, Bleiswijk, NL), and propagated at 37°C in a 
5% CO2 humidified atmosphere. Cell lines were routinely 
tested for Mycoplasm infection using MycoAlert (Lonza, 
Basel, Switserland).
Cell culture and transfections
Using a lentiviral system, stably transfected 
LMWPTP knockdown cells were generated. In brief, 
HEK293T cells were transfected with LMWPTP or non-
target control shRNA (Sigma-Aldrich, St. Louis, USA) 
and viral plasmid, generating virus containing medium. 
CRC cells were incubated with the conditioned medium 
for 48 hours after which transfected cells were selected 
using puromycin (2 μg/ml, Sigma-Aldrich, St. Louis, 
USA).
Western blotting
Subconfluent cells were lysed on ice in 2x 
concentrated Laemmli buffer (100 mM Tris–HCl (pH 6.8), 
200 mM dithiothreitol, 4% SDS, 0.1% bromophenol blue 
and 20% glycerol) and samples were boiled for 10 min. 
Cell extracts were resolved by SDS–PAGE and transferred 
to polyvinylidene difluoride membranes (Merck chemicals 
BV, Amsterdam, the Netherlands). Membranes were 
blocked in 50% odyssey blocking buffer (LI-COR 
Biosciences, Lincoln, NE) in PBS/0.05% Tween-20 and 
incubated overnight at 4°C with primary antibody. After 
washing in PBS-T, membranes were incubated with 
IRDye® antibodies (LI-COR Biosciences, Lincoln, NE) 
for 1 h. Detection was performed using Odyssey reader 
and analyzed using manufacturers software. For antibodies 
used see Supplementary Table 1.
Immunoprecipitation and phosphatase assay
To quantify the phosphatase activity, cells were lysed 
with 200 μl of Lysis Buffer (20 mM HEPES, pH7.7 with 
2.5 mM MgCl2, 0.1 mM EDTA, 1 mM PMSF, 1 mM DTT, 
10 μg/mL aprotinin and 10 μg/mL leupeptin) on ice for 
2 h. After clarifying by centrifugation, the cell extracts were 
incubated overnight at 4°C under rotation with antibodies 
against LMWPTP (Acp1 antibody, sc-100343, Santa 
Cruz Biotechnologies, Dallas, Tx) PTP1B (PTP1B antibody, 
sc-14021, Santa Cruz Biotechnologies, Dallas, Tx) or SHP-
1 (SH-PTP1 antibody, sc-7289). A/G-Sepharose beads were 
added to cell homogenates and incubated for 2 h at 4°C. 
Cell extracts were washed 3 times with lysis buffer and 
2 times with acetate buffer (100 mM pH5.5). The precipitate 
was resuspended in acetate buffer containing PNPP as 
substrate. 45 min after incubation at 37°C, equal volume of 
1N HCl was added, and phosphatase activity was measured 
using a spectrophotometer at 405 nm.
Cell viability assay
Using a colorimetric MTT (3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide assay, proliferation 
was measured. In brief, 10.000 cells were seeded in 
96 wells plate, after 24, 48, 72 or 96 hours 5 mM MTT 
was added, and incubated for 2 hours. Next, cells were 
resuspended in 100 μl of Dimethyl sulfoxide and 
wavelength was measured using a spectrophotometer at 
490 and 595 nm. Each assay was performed at least three 
times in duplicate.
Cell cycle analysis
Cell cycle analysis was performed by staining the 
cells for 1 h in sodiumcitrate-dihydrate (1 g/L) solution, 
containing 20 μg/mL propidiumiodide, 0.1% triton-X100 
and 100 μg/mL ribonuclease A. The cell cycle distributions 
were analyzed using Modfit LT software. Each assay was 
performed twice.
P-Glycoprotein expression levels
P-gp expression levels were measured using 
standard flow cytometric analysis. Cells were incubated 
with primary anti-mouse P-gp antibody (Imunnotech, 
Marseille, France). After washing, cells were incubated 
with anti-mouse FITC labelled antibody, and analyzed 
by flow cytometry. Data is shown as mean fluorescence 
intensity (MFI).
Adhesion assay
50.000 cells were loaded into 96 wells plates and 
allowed to adhere for different time points to the plate 
surface either coated with fibronectin, or without coating. 
After 30 min, 1 h and 1.5 hours non-adherent cells were 
washed away. After 1.5 hours, MTT was added to the plate 
in order to quantify the amount of adhered cells. Cells 
adhering to fibronectin coating for 1.5 hours served as 
control. Assays were performed twice, with 8 duplicates 
averaged in each assay.
Scratch migration assay
Cells in 6-well plates were grown to semi 
confluence. Using a yellow Gilson pipette tip simple 
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scratch wounds were made. After washing the cells, the 
persisting areas of clear plastic were measured at 0, 24 
and 48 hours using Axiovision 3.0 software (Carl Zeiss 
Vision GmbH) and the reduction in scratch wound area 
from time 0 was calculated. Each assay was performed 
twice, in duplicate.
Cell migration assay “ring barrier system”
Cell migration assays were performed using the 
ring-barrier migration assay previously described [34]. 
Briefly, sterile coverslips placed in an Attofluor incubation 
chamber were coated with gelatin (1 mg/ml) and incubated 
for 1 h at 37°C, prior to cell seeding. A removable circular 
sterile migration barrier was inserted into the chamber, 
which prevents cell growth in the center of the coverslip. 
4×105 HCT116 and 2,5×105 CACO-2 knockdown and 
control cells were seeded around this barrier and the rings 
were incubated at 37°C for 24 h, thereby generating a 
confluent monolayer in the periphery and a cell-free area 
in the center of the coverslip. After removing the migration 
barrier, time-lapse imaging was conducted at 37°C under 
humidified 5% CO2 air flow for 24 h on an Axiovert 100M 
inverted microscopes, equipped with an AxioCam MRC 
digital cameras, using a 10X/0.30 Plan-Neofluar objective 
(Carl Zeiss B.V., Sliedrecht, Netherlands). Time-lapse 
movies (images taken every 12 min) were used to quantify 
cell migration using AxioVision 4.5 software. For each 
movie, 10 cells at the migration front were randomly 
selected and tracked for the analysis. The net track 
movement of cells in 24 h was termed ‘total migration’, 
while the directional movement of cells to the cell-free 
center of the coverslip was termed ‘effective migration’. 
Migration efficiency was determined as the percentage of 
directional movement over the total track distance. For 
each cell line, at least three independent migration assays 
were performed.
3D-migration using cell dispersion assay
Cytodex-3 microcarrier beads (Sigma–Aldrich) 
were mixed with 5x105 CACO-2 and HCT116 knockdown 
and control cell suspensions, considering a density of 40 
cells per bead, and incubated at 37°C for 6 h with gentle 
mixing. The bead suspension was transferred to a 25 cm2  
tissue culture flask and incubated for 48 h to ensure 
complete coating of beads and to remove unattached cells. 
Coated beads were embedded in 1.6 mg/ml collagen gel 
(collagen: modified Eagle’s medium:7.5% w/v NaHCO3 
in the ratio 8:1:1) in a 24-well plate such that each well 
had approximately 150 beads. Plates were incubated 
at 37°C for 2 h for the beads to settle in the gel and the 
polymerized gels were covered with 500 μl DMEM, 
10% FBS, 1% p/s. Cell dispersion was measured as the 
maximum migrated distance from the surface of the bead 
into the collagen gel. All measurements were performed 
using AxioVision 4.5 software and assays were performed 
three times in duplicate. Two-way analysis of variance was 
performed to calculate P-values.
Immunofluorescence
Subconfluent cells, cultured on glass coverslips, 
were fixed 15 min in 4% paraformaldehyde in PBS and 
permeabilized in 0.1% Triton-X100 in PBS (PBS-T). Actin 
filaments were stained with 10 μg/mL phalloidin-TRITC 
in PBS-T. Cell nuclei were stained with 200 ng/mL DAPI 
(4’, 6’-diamidino-2-phenylindole) in PBS-T for 30 min 
and coverslips were mounted using Vectashield mounting 
medium. Immunofluorescent images were taken using Zeiss 
LSM510Meta confocal microscope with x40 OilFLUAR 
lens. Morphometric analysis was performed by measuring 
the length/width ratio of 26 randomly selected cells.
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